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Vascular calcification: A stiff challenge for the nephrologists—
Does preventing bone disease cause arterial disease? There has
been an explosion of interest in vascular calcification in the last
5 years. Four key “germinal” findings have fallen onto very fer-
tile soil. First, on the background of an increasing cardiovascular
disease burden it has been found that at least cross-sectionally,
and in a limited fashion prospectively, achieved dialysis plasma
phosphate levels are linked to all-cause and cardiovascular mor-
tality. Second, there are increasing reports of calcific uremic ar-
teriolopathy in Australia and the United States. Third, we know
know that the mechanical properties of the carotid artery, and
the aorta, have a profound influence on survival for dialysis
patients. Vascular calcification itself (as assessed by x-ray films
and ultrasound) has been linked to aortic stiffness. Fourth, in-
creasing numbers of studies are showing extremely extensive
coronary artery calcification (CAC) in dialysis patients, even at
a young age. From these apparently unlinked observations the
following assertion has been posited—that in the widespread
(over) use of calcium-containing oral phosphate binders (OPB)
to prevent uremic osteodystrophy in our dialysis population we
have unwittingly accelerated widespread uremic vasculopathy
and thereby contributed to premature cardiovascular mortality.
It is the purpose of this article to discuss vascular calcification
(and particularly CAC) in dialysis patients as we understand it
today. We will review the published series, with special reference
to the Sevelamer Treat to Goal trial and also discuss the new
Kidney Disease Outcome Quality Initiative (K-DOQI) guide-
lines on the use of phosphate binders in chronic kidney disease.
There has been an explosion of interest in vascular cal-
cification in the last 5 years. At the 2002 and 2003 Amer-
ican Society of Nephrology (ASN) meetings, and in the
recent World Congress in Berlin, there were dozens of ab-
stracts, and several sessions, where these issues were pre-
sented and debated. A few years ago we doubt whether
the abstracts would have been accepted, or the sessions
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been planned. What has happened—why this sudden in-
terest in chalky arteries?
Every so often, there is either a new idea, or, more
frequently, a new way at looking at an old problem.
Four key “germinal” findings have fallen onto very fer-
tile soil. First, on the background of an increasing cardio-
vascular disease burden it has been found that at least
cross-sectionally, and in a limited fashion prospectively,
achieved dialysis plasma phosphate levels are linked to
all-cause and cardiovascular mortality [1, 2]. This effect
persists in large datasets [e.g., United States Renal Data
System (USRDS)] even after allowance has been made
for a variety of potential confounders.
Second, there are increasing reports of calcific uremic
arteriolopathy in Australia [3] and the United States [4,
5]. This once very rare condition is now being seen as a
necrotizing panniculitis or ascending acral gangrene typ-
ically in obese white diabetic women, some on warfarin
[6] (see later).
Third, we now know that the mechanical properties of
the carotid artery, and the aorta, have a profound influ-
ence on survival for dialysis patients [7, 8]. Vascular calci-
fication itself (as assessed by x-ray films and ultrasound)
has been linked to aortic stiffness, and to patient survival
[9–11] and one possible determinant of arterial calcifica-
tion is thought to be ingestion of calcium-containing oral
phosphate binders (OPB).
Fourth, increasing numbers of studies are showing ex-
tremely extensive coronary artery calcification (CAC) in
dialysis patients, even at a young age [12, 13]. Here again,
in some studies a link has been reported between the
ingested dose of calcium-containing OPB and CAC [13–
15]. It has recently been shown that progressive CAC
on continued calcium salt administration can be largely
abolished by the use of sevelamer (Renagel) in place of
calcium-containing OPBs [14].
From these apparently unlinked observations the
following assertion has been posited—that in the
widespread (over) use of calcium-containing OPB to
prevent uremic osteodystrophy in our dialysis popula-
tion we have unwittingly accelerated widespread uremic
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vasculopathy and thereby contributed to premature car-
diovascular mortality. We have put bones ahead of ves-
sels. A broken bone is painful and debilitating, but rarely
fatal. With “broken” coronary arteries, or aorta, the im-
plications are obvious.
We in the renal community are in the dock. The charges
have been read out by the prosecution. To answer these
charges we have to address a simple question—does oral
consumption of calcium salts lead to vascular calcification
and hence increased vascular stiffness in patients on dial-
ysis? Although this is a “renal” question, nephrologists
are not the only ones to have questioned a link between
calcium intake and cardiovascular disease [16, 17].
How should we plead? Our defense should be based on
a critical examination of the “evidence chain” that under-
lies the prosecution case. Will there be a “smoking gun”
or is the prosecution case merely a bald and insubstan-
tial narrative given passing verisimilitude by recourse to
circumstantial evidence, fervor and commercial spin?
It is the purpose of this article to discuss vascular calci-
fication (and particularly CAC) in dialysis patients as we
understand it today. We will review the published series,
discuss the pivotal sevelamer Treat to Goal trial in detail
[14], report important information on CAC and vascular
calcification, answer the charges as stated, and review the
options for therapeutic change. The new Kidney Disease
Outcome Quality Initiative (K-DOQI) guidelines on the
use of phosphate binders in chronic kidney disease will
also be discussed.
RISK-BENEFIT RATIOS FOR INTERVENTIONS
As a prelude we can remind ourselves that all treat-
ments incur risk, and we hope that the benefit that also
accrues will outweigh this risk. Very often we set out with
one “care paradigm” aimed at one problem, only to find
that in applying that paradigm we unwittingly have cre-
ated something worse. The irony here is that with the
widespread and effective use of aluminum-based OPBs to
counter “renal osteodystrophy” (mainly hyperparathy-
roidism) there was a large price to pay (allied to exposure
to aluminum in dialysate) for a small number of patients.
Thus there was a retreat from aluminum to calcium for
phosphate binding. This also seemed sensible as it was
perfectly possible to induce a negative calcium balance
across dialysis, and osteopenia is a common finding in
dialysis patients. But now some say that calcium is the
aluminum de nos jours?
Although not in the scope of this article we should
be mindful of other potential therapeutic pitfalls. For
example, are we, by systematically “overloading” pa-
tients with intravenous iron in a short-sighted attempt to
improve erythropoiesis, unwittingly increasing suscepti-
bility to both infection and to oxidative stress and cardio-
vascular disease [18]? In the transplantation setting, is
the chronic exposure to rejection-preventing calcineurin
Table 1. Demographic and therapeutic changes
Demographic changes
More women, older more complex
patients, more diabetics
Therapeutic changes
Water softening, deionization 1960s to 1980s
Abandonment of aluminum as an oral
phosphate binders
1980 to 1985
Widespread use of calcium-containing
oral phosphate binders
Late 1970s, early 1980s
Widespread use of vitamin D and its
metabolites to treat renal
osteodystrophy
Late 1970s
Declining use of bone
biopsy/radiologic skeletal survey
1980s to present day
Increasing use of intact parathyroid
hormone measurements
noninvasively to assess bone health
1980s to present day
Increased numbers of patients
dialysed, with a “one size fits all”
approach to dialysate preparation
Progressive trend
Shorter hours—adequacy focused on
low-molecular-weight solutes
1985 onward
inhibitors leading to more chronic interstitial fibrosis and
premature graft loss [19]? These worrying examples all
have a common theme—short-term advantage, long-term
adverse consequences.
MANY CHANGES IN PATIENTS AND DIALYSIS
PRACTICE
Over the last three decades there have been many
changes in the type of patient whom we treat, and what
we have routinely done to these patients. He/she is likely
to be older, with more comorbid conditions, cardiovascu-
lar and other, and more likely to have impaired glucose
tolerance. These changes are listed in Table 1. We need to
consider the integrated impact of all of these, and not to
be selective. Older age (both “natural” and also progeria
syndromes [20]), diabetes, and uremia are each associ-
ated with vascular calcification [21]. There are also spo-
radic or familial infantile vascular calcification conditions
[22, 23]. Of course, as we shall see, vascular calcification is
present even in young dialysis patients, and this requires
explanation and interpretation.
Most body calcium, about 99.9%, is in the form of
bone. The plasma calcium reflects body stores very badly.
Plasma and intracellular calcium levels are kept tightly
regulated, as many vital metabolic processes tolerate ma-
jor departure from the normal range poorly. The skeleton
is a highly effective buffer to keep plasma calcium in the
normal range. Calciotropic hormones such as parathy-
roid hormone (PTH) and vitamin D play a pivotal role. It
should be remembered though that there are PTH recep-
tors in many tissues, including the vasculature. The same
is true for the distribution of the vitamin D receptor [24].
Thus calcium and phosphate can be deposited into bone,
or liberated from bone, as needed. Adjustments to in-
gested calcium can be made through the gastrointestinal
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effects of vitamin D; renal excretion can also be minutely
regulated. Self-evidently with renal disease and its treat-
ment most of these important regulatory pathways are
defective or disabled.
WHAT IS VASCULAR CALCIFICATION?
Contiguglia et al [25] showed that the calcium in ar-
terial calcifications taken from vessels of uremic subjects
was made up of hydroxyapatite crystals (the same form as
is seen in the skeleton). Interestingly in calcified stenotic
regions of arteriovenous fistulas (at sites of vessel wall
injury) the material is a “brushite” form of calcium (mag-
nesium) phosphate (“Whitlockite”) which has been re-
ported in the elastic lamina chiefly in the inner two thirds
of the media of human aorta [26]. Calcium oxalate crys-
tals are only relevant to systemic oxalosis, where vessel
injury calcification and gangrene are well-described [27].
Calcification in the vessel wall occurs in two distinct
sites. Atherosclerotic plaques as they mature and start
to become “complex” typically have associated calcifica-
tion. This is a hallmark of advancing atherosclerosis, and
is seen in the aorta, coronary, and other muscular arter-
ies. This process starts in childhood and adolescence [28].
The elastic lamina of large and medium-sized arteries can
also calcify (particularly around fractured disorganized
elastin fibers), this is “medial” calcification, responsible
for “pipe-stem” or “tram-line” appearances (once known
as Monckeberg’s medial calcinosis [29]) as considerable
lengths of the arterial tree calcify (Figs. 1 and 2). Both the
giraffe and the African elephant also show this type of ar-
terial pathology as they age [30]. This process was also ob-
served in post-mortem histopathologic specimens from
Egyptian mummies from the XXIst (circa 950 BC) dy-
nasty (Jurgen Floege, personal communication). It would
be a mistake not to consider these processes separately,
as the vascular consequences (occlusion with atheroscle-
rosis and vascular stiffening through medial calcification)
are different. A recent report using plain x-ray films and
ultrasound to delineate hemodialysis patients with inti-
mal or medial femoral/carotid calcifications showed that
the presence of any vascular calcification was associated
with reduced survival—but that intimal lesions (seen in
older patients) conferred a worse prognosis compared
to medial calcification (seen in younger dialysis patients)
[15]. It is likely that in some vessels (e.g., coronary arter-
ies), intimal and medial vascular calcification, can colo-
calize. Interestingly, the promotors and risk factors for
both types of vascular calcification though similar are not
identical—unlike atheroscleoris, medial vascular calcifi-
cation is not an inflammatory process per se [31].
Large elastic, medium-sized muscular arteries, and ar-
terioles, can all calcify. Veins hardly ever undergo these
changes [unless injured [32], or arterialized as after coro-
nary artery bypass grafting (CABG) and arteriovenous
Fig. 1. Plain x-ray film showing tram-line medial calcification.
Fig. 2. Histology of medial calcification (courtesy of Dr. Sharon Moe,
University of Indiana, Indianapolis, Indiana, USA).
fistula formation]. Patients with pulmonary hypertension
can develop calcification in the pulmonary arterial tree
[33].
For many years it was thought that it was physico-
chemical factors alone that regulated calcification (i.e.,
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Fig. 3. Fluoroscopic calcification in coronary arteries—comparison
with coronary angiogram.
calcium-phosphate product) and pH (alkaline pH favor-
ing calcification) [34]. However, Virchow with typical lu-
cidity and perception had pointed out in the 1850s the
similarity between ossification and calcification [35], and
ossification it had long been realized was a more elabo-
rate regulated process involving the synthesis of a matrix
which was then calcified. These seminal observations and
deductions were destined for a long gestation.
HOW CAN WE DETECT, ASSESS, AND
QUANTIFY VASCULAR CALCIFICATION?
The simplest technique is plain x-ray films. Pipe-stem
calcification of the tunica media and internal elastic lam-
ina produce spectacular films (Figs. 1 and 2). Often the
patient has no, or nonspecific, symptoms however dra-
matic the x-ray films may appear. However, despite the
simplicity of this technique it is both insensitive and diffi-
Fig. 4. Xerography (mammography) showing medial calcification in
breast arteries.
cult to quantify. Some degree of differentiation between
intimal and medial calcification may be inferred from the
use of plain films and ultrasound of the vessels to demon-
strate patency and no luminal lesions [15]. Fluoroscopic
appearances of valvular and coronary calcifications have
been noted for decades (Fig. 3). Low-intensity (“xerora-
diography”) techniques such as mammography can show
vascular calcification well in the context of soft tissue
densities (Fig. 4). Vascular ultrasound can show calcified
plaques, and calcified media, quite well. More recently,
intravascular ultrasound and optical coherence tomogra-
phy have been used, and these offer further refinements
in sensitivity.
But of all these techniques it is computed tomography
(CT) scanning (Fig. 5) that allows both detection and also
quantification of the extent and the severity of vascular
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Fig. 5. Computed tomography (CT) scan of thoracic aorta showing
extensive calcification.
calcification (though not a differentiation between inti-
mal and medial calcium deposition). Electron-beam CT
scanning with its rapid acquisition time (and relatively
poor spatial resolution) has been developed with cardiac
gating to examine coronary artery calcification (Fig. 6).
Modern multislice/helical CT scanning machines now of-
fer excellent spatial (but poorer temporal) resolution for
large and medium sized arteries.
The origins of interest in this area were in histologic
examination of postmortem arterial specimens. This re-
mains the qualitative “gold standard.” Quantification is
very taxing.
There are other techniques that can show the presence
of calcium, at microscopic level, but not establish its pres-
ence in vessels as opposed to a more diffuse interstitial
deposition. These include ultrasonic/echocardiographic
signal backscatter analysis [36], energy subtraction radio-
graphy [37], and nuclear medicine bone tracer techniques
[38].
Fig. 6. Electron beam computed tomography (CT) scan showing se-
vere calcification in coronary arteries.
BIOLOGY OF VASCULAR CALCIFICATION IN
RENAL AND NONRENAL PATIENTS
Although vascular calcification has traditionally been
considered to be a physicochemical “passive” precipita-
tion in the tunica media of vessel walls, there are abun-
dant animal and clinical data supporting the notion that
more important than this passive process is an active or-
dered and regulated process. There are many complex
bone-synthetic pathways (which closely resemble skele-
tal osteogenesis) in the vessel wall that involve a variety
of genes and proteins with intimate involvement in min-
eral metabolism. This complexity is as true for calcifica-
tion of complex atherosclerotic plaques as it is for medial
arterial calcification. Various bone-related proteins such
as osteonectin, osteopontin, PTH, PTH-related peptide,
osteroprotegerin, and bone morphogenic protein can be
found in atherosclerotic plaques and in sites of medial
arterial calcification [39, 40].
The evidence that what is occurring in vessel walls is ec-
topic ossification comes first from clinical and histologic
descriptions of structures resembling bone and even bone
marrow, second that the form of calcium phosphate crys-
tals found are hydroxyapatite (as in the skeleton), third
matrix vesicles, which in bony ossification serve as the fo-
cus for ossification initiation, are also seen in vessel walls
in proximity to calcified areas, and finally the immunocy-
tochemical demonstration of a number of characteristic
bone-related proteins such as collagen I and a number of
noncollagenous bone matrix proteins.
In nephrology we have been interested in the relatively
small amount of information that has come from short-
term or cross-sectional human studies of patients on
dialysis as a result of diverse renal pathologies. What is
singularly lacking is any good evidence about the role of
genetic factors as well as the obvious environmental ones.
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Table 2. Main bone morphogenic proteins and noncollagenous bone matrix proteins and genes involved in vascular calcification in animals and
humans
Protein Function Vascular calcification
Osteopontin Antiapoptotic signal for osteoclasts; chemotactic
factor for MC and MP
Recruitment of MP into area of vessel injury; osteopontin
knockout mice develop stronger skeleton; osteopontin
restrains mineralization
Osteoprotegerin/RANKL Inhibitor of osteoclastogenesis; member of tumor
necrosis factor-a receptor superfamily
OPG inhibited by cyclosporine A; OPG inhibited by
osteopontin; restrains mineralization
Matrix GLA protein Expressed in chondrocytes and vascular smooth
muscle cells and increased expression in lipid-rich
plaque
Knockout mice get dramatic early vascular calcification;
warfarin effect on gamma-carboxylation (as




Paracrine factor with potential humoral activity in
hypercalcemia of malignancy; shares PTH1
receptor with PTH; involved with normal bone
physiology
Upregulated expression by vessel injury and angiotensin
II; antagonizes procalcifying effect of vitamin D3;
down-regulates bone morphogenic protein-2
Bone morphogenic protein-2 Osteoblastic and mesenchymal differentiation Promotes ossification
Bone morphogenic protein-7 Differentiation factor; normal tubular epithelial
differentiation; osteoblastic differentiation
Null mouse has renal failure and agenesis; reverses
heterotopic calcification in animal models
Vitamin D Diverse functions through vitamin D
receptor-dependent and independent pathways
Medial calcification; vascular smooth muscle cells have
vitamin D receptors; raised calcium-phosphate product
Fetuin Synthesized in liver; soluble transforming growth
factor-b antagonist; negative acute phase reactant
Knockout mice get ubiquitous soft tissue and vascular
calcification; potent inhibitor of mineralization
Abbreviations are: MC, monocyte; MP, macrophage; OPG, osteoprotegerin; RANKL, receptor activator of NF kappaB ligand.
This is worrying, as there are abundant data from animal
models and from large clinical/epidemiologic databases
that suggest genetic factors are intimately involved with
the tendency to calcify.
There are several mouse models of accelerated vas-
cular calcification—matrix GAL protein (MGP)-null,
b-glucoronidase-deficient KLOTHO, carbonic anhy-
drase II-deficient, desmin-null, and osteoprotegerin-
null—from which we can deduce that some genes are
pivotal to the control of this process (reviewed in detail
in [41]). It is not known (yet) whether the various
forms of fetal and infantile accelerated calcification syn-
dromes (both familial and sporadic) are human man-
ifestations of single gene disorders [42]. In a recent
report of a single case of a 25-month-old infant with
advanced (and fatal) idiopathic infantile calcification
syndrome there were deficiencies of extracellular py-
rophosphate (PPi) and of PPi-generating nucleoside
triphosphate pyrophosphohydrolase (NTPPPH) in his
temporal artery lesions. Idiopathic infantile arterial cal-
cification has now been studied in 11 unrelated kin-
dreds [43], and mutations leading to inactivation of
ecto-nucleotide pyrophosphate/phospodiesterase 1 (a
cell surface enzyme which generates inorganic phos-
phate and serves as an essential physiologic inhibitor of
calcification) have been shown, Plasma cell membrane
glycoprotein-1 (PC-1) activity, associated in mice with ar-
terial and periarticular calcification, tends to support this
hypothesis [44]. Table 2 lists a selection of the gene and
protein “major players.” One genetic factor contributing
to aortic calcification in the mouse is the Dyscalc locus,
previously shown to contribute to myocardial calcifica-
tion. The Dyscalc locus, on proximal mouse chromosome
7, segregated with vascular calcification in a large cross
between susceptible strain DBA/2J and resistant strain
C57BL/6J. Further evidence was observed by analysis of
recombinant inbred strains derived from various suscep-
tible and resistant parental strains [45].
Data derived from large clinical studies support the
hypothesis that genetic/familial factors/polymorphisms
have direct relevance. However, many studies are under-
powered, and data from large populations are required.
We lack such information about renal cohorts.
After adjusting for risk factors including age, gender,
fasting glucose level, systolic blood pressure, pack-years
of smoking, and low-density lipoprotein (LDL) choles-
terol, 41.8% of the residual variation in CAC quantity in
patients with coronary disease was attributable to genetic
factors (P = 0.0003) in a large study (698 asymptomatic
subjects) [46].
Members of 1256 Pima Indian nuclear families with
3339 offspring were examined radiologically for medial
arterial calcification of the feet. Controlled for age, gen-
der, diabetes, serum cholesterol, and blood pressure, off-
spring of one parent with medial arterial calcification
(MAC) had 3.3 (95% CI 1.5 to 7.6) times the odds of
MAC, as did offspring of parents without MAC while
offspring with both parents affected had an even higher
risk (odds ratio, 8.1; 95% CI 3.4 to 18.8). These findings
suggested that the factors responsible for the familial clus-
tering of MAC may be different from those for diabetes
[47].
Finally, a large study examined CAC by electron beam
CT in type 2 diabetics. Extent of CAC, adjusted for age,
was positively associated with male sex (P = 0.0003),
reduced high-density lipoprotein (HDL) (P = 0.02),
albumin-to-creatinine ratio (P = 0.008), and cigarette
pack-years (P = 0.03). CAC was also positively associated
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with a history of angina, myocardial infarction, stroke,
and vascular procedures (all P < 0.01). CAC, adjusted
for age, gender, race, and diabetes status, was heritable
(h2 = 0.50; P = 0.009). In multivariate analysis with ad-
ditional adjustment for HDL, body mass index (BMI),
hypertension, and smoking, h2 = 0.40 (P = 0.038). These
results suggested that strong (independent) genetic fac-
tors as well as environmental factors contribute to the
variance of CAC in individuals with type 2 diabetes [48].
Relationships between the E-selectin S128R polymor-
phism and CAC, a marker of atherosclerosis detected by
electron beam CT, were examined in 294 asymptomatic
women aged 40 to 88 years and 314 asymptomatic men
aged 30 to 80 years from the Epidemiology of Coronary
Artery Calcification Study. The E-selectin polymorphism
was not associated with presence of CAC in men of any
age or in women over age 50 years. In women 50 years of
age or younger the E-selectin polymorphism was signifi-
cantly associated with presence of CAC after adjustment
for age, BMI, systolic blood pressure, ratio of total choles-
terol to HDL cholesterol, and smoking [49].
The A-7 or Ala 83 alleles of the MGP gene may con-
fer an increased risk of plaque calcification and myocar-
dial infarction; however, the observed relationships were
weak or limited to subgroups of patients and therefore
need further confirmation [50].
A large autopsy series comprised 700 Caucasian
Finnish men, aged 33 to 70 years (The Helsinki Sud-
den Death Study). Coronary stenosis and surface area
of atherosclerotic changes (fatty streaks, fibrous plaques,
complicated lesions, and calcification) were measured
and the presence of myocardial infarction and coronary
thrombosis recorded. Tumor necrosis factor (TNF)-a and
TNF-b genotypes were determined. Men with TNF-a 22
or TNF-b 11 genotype tended to have more fibrous le-
sions and calcification in their coronary arteries [51].
Patients with coronary artery disease and the
angiotensin-converting enzyme (ACE) DD genotype had
a significantly higher incidence and greater extent of coro-
nary lesion calcification, as determined by intravascular
ultrasound (IVUS). This finding indicated that the ACE
I/D gene polymorphism was related to the development
or progression of atherosclerotic plaque calcification [52].
Thus far no study has attempted to examine any of the
above polymorphisms, or the Vitamin-D receptor poly-
morphism, in the context of renal failure patients. Such
work is required urgently.
Potentially important “leitmotiven” in this dense or-
chestral symphony include the potential for hyperphos-
phatemia (e.g., >1.4 mmol/L) to change the phenotype
of human aortic vascular smooth muscle cells in vitro
from contractile to secretory in a fashion dependent on
normal sodium-phosphate cotransport, Pit1, leading to
up-regulation of many genes associated with matrix min-
eralization [53].
Primary hyperparathyroidism has been increasingly
recognized as a risk factor for cardiovascular disease—
through calcification, hypertension, and left ventricular
hypertrophy [54, 55]. Secondary (and tertiary) hyper-
parathyroidism has a long association with cardiovascular
pathology. Indeed, PTH as a uremic toxin has a rich his-
tory [56]. Different studies at different times have linked
mortality on dialysis to excess phosphate, excess calcium
or PTH. In the study of Klassen et al [57] of the effect of
pulse pressure on hemodialysis mortality, calcium levels
did predict mortality on dialysis in a multivariate analy-
sis of survival culling data from a 12-month period, but
neither calcium, phosphate, calcium-phosphate, nor PTH
affected the relationship between pulse pressure and
mortality, which was much stronger. Interestingly, in non-
renal patients with controlled dyslipidemia it has recently
been reported that increases in pulse pressure best pre-
dicted progressive vascular calcification of the aortic wall
[58]. Thus, increased vascular stiffness begets calcifica-
tion, which in turn begets increased vascular stiffness.
Vitamin D therapy has been recognized for decades
as a potential vascular toxin, particularly in excess. Vi-
tamin D has diverse, concentration-dependent, effects,
via—but also independent of—the vitamin D receptor,
promoting plaque calcification and atherosclerosis [59,
60]. Even in the earliest days of vitamin D usage (as an
“extract” of ergosterol), its potent ability to “calcify” pre-
dominantly the medial layer of arteries was noted in ani-
mals [61, 62] and in humans [63, 64]. With pharmacologic
doses of vitamin D there is often hypercalcemia, and ele-
vated calcium-phosphate product, which per se can accel-
erate extraosseous calcification. The postmortem study
by Milliner et al [65] of soft tissue calcifications in pe-
diatric patients showed an association between vitamin
D metabolite usage and vascular calcification (no asso-
ciation was found for calcium and phosphate). The plain
x-ray study by Goldsmith et al [21] of vascular calcifica-
tion in hemodialysis patients also showed an association
between vitamin D metabolite levels and the extent and
progression of vascular calcification. One mechanism that
can be independent of any effect of vitamin D on plasma
calcium has come from the work of Jono et al [66] where
it has been shown that 1,25(OH)2D3 exerts a stimulatory
effect on vascular calcification through direct inhibition
of the expression of PTH recombinant protein (PTHrP)
in bovine vascular smooth muscle cells, as an endogenous
inhibitor of vascular calcification. Moreover, the stimu-
latory effects of 1,25(OH)2D3 on alkaline phosphatase
activity and osteopontin expression may contribute to its
promoting action in vascular calcification.
Further indirect support for a potentially important
role for vitamin D metabolites in the genesis of cardio-
vascular disease comes from a recent retrospective report
of increased mortality in North American hemodialysis
patients taking calcitriol rather than paricalcitol [67].
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It must be remembered, however, that in the general
(nonuremic) population there may be a different rela-
tionship between calcification and vitamin D. Braam et al
[68] has recently reported that there is a favorable effect
on large artery hemodynamics from the administration
of vitamins D and K.
Leptin (in excess in obesity, old age, type II diabetes
uremia) has receptors on aortic vascular smooth muscle
cells, and has been shown in vitro to promote vascular
calcification of (bovine) vascular cells [69].
Oxidized lipids can induce inflammation and en-
dothelial/vascular smooth muscle cells damage as an
integral part of atherosclerosis (whose inflammatory—
“atherosclerotic”—nature is of equal importance to
its biologic behavior as is the more pedestrian lipid-
accumulation facet). The inflammatory response to
chemically altered lipid deposits involves monocyte-
macrophage chemotaxis and differentiation—perhaps
this atavistic response is useful in the context of lipid-
rich bacterial cell membranes which stimulate the im-
mune response appropriately? Certainly the calcification
in the context of atherosclerosis can be regarded as in-
flammatory. Nitta et al [70] examined the expression of
osteopontin in atherosclerotic aortas of hemodialysis pa-
tients and performed a prospective longitudinal study
by using CT scans to detect aortic calcifications and by
measuring the plasma osteopontin concentration by
enzyme-linked immunosorbent assay (ELISA) in 36
hemodialysis patients and in 35 healthy volunteers. By im-
munohistochemical staining, osteopontin was abundantly
localized in atherosclerotic plaques of hemodialysis pa-
tients. The macrophages surrounding the atheromatous
plaques were identified as the osteopontin-expressing
cells. The concentration of soluble plasma osteopontin
was significantly higher in hemodialysis patients com-
pared to concentrations in age-matched healthy volun-
teers (837.3 ± 443.2 ng/mL vs. 315.1 ± 117.4 ng/mL)
(P < 0.01). The osteopontin concentration was positively
correlated with the aortic calcification index in hemodial-
ysis patients (r = 0.749, P < 0.01). However, the case for
inflammation directly driving pure medial aortic vascu-
lar calcification may not be so clear-cut. Proudfoot and
Shanahan [31] have emphasized the importance of apop-
totic bodies in the elastin layer of the vessel media acting
as crystallization nidus in medial calcification rather than
the association of inflammatory cells with chemically al-
tered lipids in intimal plaques as is seen in atherosclerosis
[31].
It is important also to note that increased arterial cal-
cification in the context of lower HDL—leaving unap-
posed the action of oxidized-LDL—has been reported in
both renal and nonrenal contexts [71, 72]. Also, Parhami
et al [73] have recently shown that when treated with
HDL, alkaline phosphatase activity, a marker of os-
teogenic differentiation of osteoblastic cells, was signif-
icantly reduced in calcifying vascular cells. Prolonged
treatment with HDL also inhibited calcification, further
supporting the antiosteogenic differentiation property of
HDL when applied to vascular cells. HDL inhibited the
osteogenic activity that was induced by inflammatory cy-
tokines interleukin (IL)-1b and IL-6 as well as by min-
imally oxidized LDL. HDL also partially inhibited the
IL-6-induced activation of signal transducer and activa-
tor of transcription 3 in calcifying vascular cells, sug-
gesting that HDL may inhibit cytokine-induced signal
transduction pathways. The inhibitory effects of HDL
were mimicked by lipids extracted from HDL but not by
HDL-associated apolipoproteins or reconstituted HDL.
Furthermore, oxidation of HDL rendered it pro-
osteogenic. Taken together, these results suggest that
HDL regulates the osteoblastic differentiation and cal-
cification of vascular cells and that vascular calcification
may be another target of HDL action in the artery wall.
The theme of manipulation of natural (circulating or
local) inhibitors of the vascular calcification process (hy-
droxyapatite cystallization) is also relevant to the chronic
inflammatory milieu of uremia, as both osteoprotegerin
and alpha-2-Heremann Schmitt glycoprotein (AHSG),
or human fetuin levels decline with increasing inflamma-
tion [74]. This group has recently reported an elegant se-
ries of experiments and observations on a cross-sectional
study of 312 stable patients on hemodialysis to analyze
the inter-relation of AHSG and C-reactive protein (CRP)
and their predictive effect on all-cause and cardiovascu-
lar mortality over a period of 32 months. The capacity of
serum to inhibit CaxPO4 precipitation was tested in pa-
tients on long-term dialysis (N = 17) with apparent soft-
tissue calcifications, and in those on short-term dialysis
(N = 8) without evidence of calcifications and cardio-
vascular disease. AHSG concentrations in serum were
significantly lower in patients on hemodialysis [mean
0.66 g/L (SD 0.28)] than in healthy controls [0.72 (0.19)].
Low concentrations of the glycoprotein were associated
with raised amounts of CRP and with enhanced car-
diovascular (P = 0.031) and all-cause mortality (P =
0.0013). Sera from patients on long-term dialysis with low
AHSG concentrations showed impaired ex vivo capacity
to inhibit CaxPO4 precipitation. Reconstitution of sera
with purified AHSG returned this impairment to normal.
Fetuin deficiency appears to be associated with inflam-
mation and may thus link vascular calcification to mor-
tality in patients on dialysis [75, 76] and possibly also in
other conditions associated with chronic inflammation.
Links between vascular calcification and chronic inflam-
mation/raised cytokine levels have been demonstrated
for dialysis patients [77, 78].
The mechanism of action of human fetuin is now being
unraveled. It has recently been shown to play an impor-
tant role in the clearance of apoptotic cells by augment-
ing phagocytosis [79]. Apoptotic cell bodies are a possible
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crystal forming nidus in medial arterial calcification. In rat
serum fetuin can inhibit the precipitation of hydroxyap-
atite from supersaturated solutions of calcium and phos-
phate in vitro and this is accompanied by the formation
of the fetuin-mineral complex (FMC), a high-molecular-
weight complex of calcium phosphate mineral and the
proteins fetuin and matrix Gla protein that was initially
discovered in serum of rats treated with etidronate and
appears to play a critical role in inhibiting calcification in
vivo [80]. There may be yet other fetuin-like compounds.
In a recent study a 24 kD protein was found, similar in
domain structure to fetuin and, like fetuin and MGP, con-
taining several residues of phosphoserine and accumu-
lating in bone. Exogenous spp24 associated strongly with
FMC when added to serum containing it. These observa-
tions suggest that spp24 may, like fetuin and MGP, play a
role in inhibiting calcification [81].
MGP is expressed exclusively in mice in the growth
plate chondrocytes and in vascular smooth muscle cells.
It is a tissue-bound inhibitor of calcification, as opposed
to soluble fetuin. Mice with inactivating mutations in both
alleles of the MGP encoding gene prematurely calcify the
growth plate cartilage leading to skeletal deformity and
osteoporosis. MGP knockout mice show extreme gener-
alized medial arterial calcification and die from vascular
disease prematurely (reviewed in detail in [41] and in
[82]).
Core-binding factor alpha(1) (Cbfa1) is an essential
transcription factor for osteoblastic differentiation and
osteogenesis. Bone morphogenetic protein (BMP) is also
a powerful inducer of differentiation of pluripotent mes-
enchymal cells to osteoblast lineage and bone formation.
Recent studies suggest that Cbfa1 plays a critical role
during BMP-induced osteoblastic differentiation through
association with cytoplasmic BMP signaling molecules,
Smads [83]. Moe et al [84] examined sections of the infe-
rior epigastric artery from uremic patients for the pres-
ence of Cbfa1 and type I collagen and osteopontin by
in situ hybridization and immunostaining. Also exam-
ined was the effect of pooled uremic sera from dialysis
patients on the expression of Cbfa1 in bovine vascu-
lar smooth muscle cells in vitro. Cbfa1 and osteopon-
tin were expressed in both the media and the intima in
vessels that were calcified, but there was only minimal
staining in noncalcified vessels. In vitro studies demon-
strated that pooled uremic serum, compared to pooled
control human serum, induced the expression of Cbfa1 in
bovine vascular smooth muscle cells in a time-dependent,
nonphosphorus-mediated mechanism. These results sug-
gest that Cbfa1 is a key regulatory factor in the vascu-
lar calcification observed in dialysis patients and is up-
regulated in response to many uremic toxins.
Of so far theoretic importance in humans is that fact
that the gamma-carboxylation of MGP is a vitamin K-
dependent process that is inhibited by warfarin. Warfarin
in rats leads to calcification of heart valves and the epi-
physeal growth plate cartilage. Whether this is relevant
to humans is controversial. Some have linked long-term
warfarin usage to the increasing number of cases of cal-
cific uremic arteriolopathy (Seyle’s calciphylaxis) [82, 85];
however, there are no data to support an association be-
tween large artery calcification and use of warfarin in
humans.
One of the most important factors in the pathologic
processes that lead to ectopic calcification is the calcify-
ing vascular cells (CVCs). The presence of osteocalcin—
pathognomonic of osteoblastic terminal differentiation—
suggests that central to this complex interplay resides a
cell with an osteoblastic phenotype. Demer, Tintut, and
Perhami [82] and others have derived primary vascular
smooth muscle cell cultures from explants of medial tis-
sue from normal and diseased blood vessels. These cells
adopt a calcifying phenotype which includes synthesis
of a plethora of bone-regulating proteins, either sponta-
neously or after manipulation of the culture conditions.
The origins of these CVCs is still not clear, possibly de-
rived from common marrow mesenchymal cells, as either
vascular smooth muscle cells, in the vessel media, or ad-
ventitial pericytes (for detailed review see [82]).
OTHER POTENTIALLY RELEVANT
CONTRIBUTORS TO THE PROCESS OF
VASCULAR CALCIFICATION
Cases of aggressive systemic calcinosis, calcific uremic
arteriolopathy, and arterial calcification have not infre-
quently been reported after successful renal transplanta-
tion [86–89]. While post-transplantation hypercalcemia
and hyperparathyroidism, two “dialysis” calcifying pro-
moters may very rarely persist in the engrafted patient,
hypophosphatemia (and therefore normal or often low
calcium-phosphate product) is the norm after renal trans-
plantation. Similarly the use of vitamin D and phosphate
binders of any sort after renal transplantation is very un-
usual. So other promotors of calcification need to be iden-
tified in this clinical settings (e.g., dyslipidemia which is
typical after successful renal transplantation) with drugs
like cyclosporine A and sirolimus contributing.
IS THERE A PLAUSIBLE BIOLOGIC
RATIONALE FOR THE PRESENCE OF
VASCULAR CALCIFICATION?
It can legitimately be asked what is the “function” of
vessel calcification? One plausible explanation is that it is
a manifestation of a repair response to vessel injury. Ure-
mia per se causes vessel injury (most notably at endothe-
lial cell layer level) and perhaps this repair process is
distorted by uremia and by calcium-phosphate derange-
ment? One fascinating theory compares the constant
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remodeling of the bony skeleton to stress and strain (e.g.,
the increase in bone mass on exercise), and its reduc-
tion in bed-bound patients or weightless astronauts, in
which response there is an early increase in intracellular
calcium mediated by stretch-activated cationic channels
(SA-CAT) leading to changes in cytoskeletal architec-
ture, up-regulation of anabolic bone activity manifested
by osteopontin, and increased mineralization in vitro [41].
One could speculate therefore that in response to in-
creased cyclical shear-stress strain in the vessel wall of
large arteries there would be fragmentation and fractur-
ing of elastin fibres in the tunica media, to which resi-
dent “CVCs” would respond by (medial) mineralization
[90, 91] catalyzed by “uremic factors” (e.g., phosphate,
dyslipidemia, oxidative stress, lack of inhibitors of calci-
fication) [84]. This speculation would fit beautifully with
clinical observations about the patterns and onset of vas-
cular calcification and functional vessel changes in uremic
subjects.
WHAT ARE THE IMPLICATIONS OF VASCULAR
CALCIFICATION FOR RENAL AND OTHER
PATIENTS?
Vascular calcification in the media of blood vessels has
been linked to increased stiffness of large conduit ar-
teries in renal patients [11]. This reduced vascular com-
pliance leads to increased pulse pressure, downstream
barotrauma, reduced coronary perfusion, abnormal au-
tonomic and endothelial vasomotor function. In addition,
difficulty forming vascular anastomoses (arteriovenous
fistula, CABG) or performing successful coronary arte-
rial interventions are described (angioplasty, stenting), as
are calcific emboli from heart valves and aortic plaques.
Fluoroscopic calcification at coronary angiography was
shown to have a sensitivity of 78% and a specificity of 66%
for the presence of a 50% or greater stenosis in one or
more coronary vessels in 86 dialysis patients by Marwick
et al [92]. In a recent electron beam CT-based coronary
angiographic comparison study of 282 patients (101 type
2 diabetics of whom 89 had coronary artery disease) it
was shown that electron beam CT scores for coronary
calcification had a similar sensitivity and specificity for
coronary artery disease comparing the diabetic and non-
diabetic cohorts [93].
In the nonuremic clinical setting calcium in an
atherosclerotic plaque is a marker of a complex arterial
lesion. As such use has been made of the ability to detect
vessel calcification as a marker for atherosclerosis, of-
ten in asymptomatic individuals [94]. It has recently been
shown that high coronary artery calcium scores posed
an extremely elevated risk (higher than that for abnor-
mal nuclear medicine perfusion scans) for hard end point
events (major coronary events) [95, 96]. This additional
cardiac risk was also largely independent of more tradi-
tional cardiovascular risk factors.
However, it is known that in uremia atherosclerotic
plaque is already calcified at a much earlier develop-
mental stage (at a point where luminal encroachment is
minimal) than is seen in nonuremic subjects’ vessels [97].
Schwarz et al [98] showed that coronary plaques in pa-
tients with end-stage renal failure were characterized by
increased media thickness and marked calcification, but
not the size of the plaque. It is important therefore to
approach the question of the short- and long-term im-
plications to uremic patients of the presence of vascular
calcification with an open mind.
In uremic subjects where there is so much (more) cal-
cium in vessel walls (intima and media) there may be
“stabilization” of arterial plaque lesions with the artery
“held open,” the calcium acting as it were as “nature’s
stent.” From a biomechanical perspective motion and
stress are reduced in a calcified arterial segment but an ad-
jacent noncalcified segment (in practice at the beginning
and the end of the cylinder of calcification) may para-
doxically experience more wall stress. Ex vivo analysis
of calcified plaques have suggested increased resistance
to rupture. Recent papers have challenged the classi-
cal construct, which appears valid in nonuremic subjects,
that atherosclerotic plaques containing calcium may en-
gender plaque instability and promote potential rupture
[99]. Thus, in uremia, arterial disease progression is less
toward acute plaque rupture and more toward chronic
ischemia and fibrosis through progressive luminal oblit-
eration (contributing to myocardial ischemia, fibrosis,
myocardial electrical inhomogeneity, arrhythmia, and
sudden death) and increased vessel stiffness which in the
aorta leads to increased left ventricular mass. Indeed,
acute coronary syndromes though two to three times
more common than in age-matched general populations,
are much less amplified by uremia compared to 100-fold
increases in sudden death rates, and 20-fold increases
in mortality due to heart failure/left ventricular decom-
pensation (Data from UK registries and USRDS). The
prognostic importance of coronary artery calcification in
uremic subjects is not (yet) known but is a focus of intense
interest.
Nevertheless, overall, the presence and severity of cal-
cification (a composite score taken from ultrasounds and
plain x-ray films of the aorta and carotids) was linked in
a recent series to aortic stiffness, and to patient survival
for a French hemodialysis cohort [11].
POTENTIAL THERAPIES AND REMEDIES FOR
VASCULAR CALCIFICATION: ANIMAL CLUES
There are only a few animal studies investigating agents
to retard or to regress vascular calcification. From these,
some potentially useful interventions that could be tried
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in man include the use of bisphosphonates [100], calcium
channel blockers [101], and aluminum-tanning pretreat-
ment of cardiac valves [102, 103]. As aluminum of course
is notorious in disrupting osteogenesis, it should not be
surprising that aluminum may inhibit ectopic calcifica-
tion. But it raises the question of whether today’s vascular
calcification is a result of ceasing to use an inhibitor, or
by starting to use a promotor (calcium), or both effects?
EARLY ACCOUNTS OF VASCULAR
CALCIFICATION IN RENAL PATIENTS: ROLE
OF UNBUFFERED CALCIUM AND VITAMIN
D—IS THIS “EPIDEMIC” OF VASCULAR
CALCIFICATION A NEW PHENOMENON?
There is much interest in vascular calcification
presently. But though the interest is new, and we know
that vascular calcification is very widespread in renal co-
horts, it is new, or just newly discovered, and how does it
relate to the epidemic of cardiovascular disease seen in
dialysis patients [104]?
Calcific uremic arteriolopathy has a long history,
stretching back 100 or more years, to an original de-
scription in a medical report at Guy’s Hospital [105],
and, depending on one’s prejudice, to Herod the Great
(Donald Sherrard, personal communication). Large case
series were reported at the beginning of the dialysis era in
the 1960s and 1970s [4, 106, 107]. Similarly, as we have in-
dicated vascular calcification in renal failure is not per se
news. Re-reading some of these “old” cases dating from
1855 to 1945 (88 in number and beautifully reviewed by
Mulligan in 1949 [34]) show that they were a mixture of
osteolytic metastases, primary hyperparathyroidism, and
parathyroid carcinoma and vitamin D toxicity. In nearly
all of these cases, significant hypercalcemia was a cardinal
feature.
In a clinically fairly pure cohort of long-hours dialy-
sis, patients with modest and well-defined use of vitamin
D and calcium [21] showed an association between mea-
sured 1,25(OH)2D3 levels and the extent and progression
of vascular calcification.
Can we be sure that the present vascular calcification
“epidemic” is new? May it not be that much greater
awareness of vascular calcification as an issue, and better
screening and imaging analytic techniques, have recently
helped us better to define a long-standing problem?
Autopsy studies–derived evidence
In the predialysis era Pollak et al [108] reported the
presence of vascular calcification in 18/29 patients with
secondary hyperparathyroidism. In 1969 Parfitt [109]
(then at Cedars Sinai Los Angeles) in reviewing “soft tis-
sue” calcification reported 8/16 dialysis patients with “ar-
terial calcifications.” An autopsy study from the period
1966 to 1975 of 56 dialyzed and 18 nondialyzed chronic
renal failure patients reported 44/56 dialyzed patients but
only 8/18 chronic renal failure patients had visceral (in-
cluding myocardial) calcification. Interestingly, the corre-
lation in this study between severity and anatomic extent
of calcification with bone biopsy findings, and parathyroid
gland weight and histology, was poor [110]. Terman et al
[111] reported six autopsy cases of chronic dialysis pa-
tients who demonstrated myocardial, cardiac conducting
system, and intense arterial calcifications (internal elas-
tic lamina, and medial) with little or no athersclerotic
coronary disease. Ibels et al [112] in 1979 reported 18 au-
topsies on chronic dialysis patients only one of whom had
angina. They found 92% patients with intimal thickening,
67% calcification, and abnormal internal elastic laminae
in 83% compared to control autopsy specimens. Milliner
et al [65] reported on 120 children who had died at a mean
age of about 10 years with uremia, dialysis or after trans-
plantation between 1960 and 1983 in Los Angeles; 29 had
cardiac and 12 had coronary artery calcifications.
X-ray studies–derived evidence
Meema, Oreopoulos, and de Veber [113] from Toronto,
Canada reported in 1976 an x-ray study of 364 skeletal
surveys in 152 dialysis patients. 30% of 15 to 30 year olds
and 50% of 40 to 50 year olds had vascular calcification
(most commonly medial vascular calcification at the an-
kle). Progression of anatomical extent and severity was
most marked in the nondialyzed group and interestingly
was least in the hemodialyzed group. The same group re-
ported in 1986 [114] and 1987 [115] on factors associated
with progression and regression of x-ray film disclosed
vascular calcification in chronic continuous ambulatory
peritoneal dialysis (CAPD) patients between 1980 and
1985; all had some calcification (very mild 58%, mod-
erate to severe in 42%). Progression occurred in 57%
and regression in 13%. Progression was more likely if the
plasma magnesium level was low.
In the study by Andresen and Nielsen [116] published
in 1982, the overall frequency of calcifications in ves-
sels and soft tissue was 39% in 184 patients with chronic
renal failure. Calcification was most pronounced in the
larger vessels in nondialyzed and dialyzed patients and
in small vessels in renal transplant recipients. In nondia-
lyzed patients and in dialyzed patients at the start of dial-
ysis treatment, calcifications were more commonly found
in women while in renal transplant subjects a male pre-
ponderance was seen. Renal transplant recipients, who
developed osteonecrosis or spontaneous fractures after
transplantation, showed at the time of transplantation
a higher frequency of calcifications compared to renal
transplant recipients, who did not develop these compli-
cations. In all groups a significant, higher frequency of cal-
cifications was found in patients with radiologic evidence
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of bone resorption compared to patients without resorp-
tive bone changes. Before and during chronic hemodial-
ysis and following renal transplantation the frequency of
calcifications increased, a process that occurred slowly
in nondialyzed patients and in renal transplant recipi-
ents, whereas an accelerated increase occurred in the first
15 months of the dialysis period in hemodialyzed patients.
The frequency of calcifications increased with increasing
age not only in the aorta, but also in the other vessels.
The most careful follow-up analysis study was a
derived-score x-ray series from Goldsmith et al [21]
where 38 long-term (surviving 10 to 25 years on 24 hours/
week hemodialysis) were reviewed with their annual
skeletal survey and clinicobiochemical dossiers. This
“skeletal” survey series was reanalyzed as a “vascular”
survey series. This covered the period 1970 to 1994 and
involved over 600 patient years of hemodialysis. Aorto-
iliac calcification was seen in 39% at the onset of dialysis,
the risk increasing with age. By a mean of 16 years on
dialysis 92% of patients had vascular calcification. Cen-
tral/elastic arteries could calcify independently of smaller
peripheral muscular ones. Patient age, dialysis vintage,
pulse pressure, plasma phosphate, measured plasma vita-
min D levels, and severe hyperparathyroidism [by intact
PTH (iPTH)] were associated with heavier vascular cal-
cification. Parathyroidectomy would reduce, or abolish,
further calcium accumulation in the vascular tree.
Electron beam CT studies–derived evidence
(see also below)
Electron beam CT–derived CAC scoring has shown
for adult patients already established on dialysis an 80%
to 100% prevalence of CAC. This is lower in children,
though in children on dialysis CAC progresses faster than
in healthy adult patients (William Goodman, personal
communication). Geoffrey Block has recently reported
(personal communication) that 40% of incident dialy-
sis patients, including a high percentage of diabetics just
starting on hemodialysis, did not have CAC by electron
beam CT; and only 17% had very heavy scores. This is
contrasted with a recent predialysis study of diabetic pa-
tients where the vast majority had CAC evident and to a
greater extent than nondiabetic controls [117], and which
many other studies of chronic dialysis patients, where
cross-sectionally, and with limited follow-up, there was
near universal progression of CAC (see Table 4).
We can conclude that vascular calcification was a clear
feature of patients well before calcium-containing OPBs
were available, and that further calcium accumulation
was, and is now, very common particularly once on dial-
ysis. There are many closely-linked risk factors for the
development and progression of vascular calcification, in
diverse clinical situations.
Given the different patient groups, and the increas-
ing use of much improved x-ray/electron beam CT
techniques and scoring systems to detect vascular calcifi-
cation, while it is certainly the case that vascular calcifica-
tion is common if not ubiquitous, it is not possible to say
with confidence that the epidemic of vascular calcification
is “new.” Table 3, compared with Table 1, serve to show
how much of the present “evidence” is circumstantial and
is capable of several interpretations.
ELECTRON BEAM CT STUDIES IN RENAL
PATIENTS
In the general population this (screening) technology
allows gated imaging of the heart and great vessels free
from respiratory artifact by virtue of a 100 mseconds im-
age acquisition window, compared to 300 to 500 msec-
onds time period needed for multislice CT machines.
Calcium in the vessel shown by electron beam CT sig-
nifies a complex plaque reasonably accurately, compared
with angiographic studies, and outcome data. As such use
has been made of the ability to detect vessel calcification
as a marker for atherosclerosis, often in asymptomatic in-
dividuals [94]. It has recently been shown that high coro-
nary artery calcium scores posed an extremely elevated
risk—and higher than that for abnormal nuclear medicine
perfusion scans—for “hard events” (major adverse coro-
nary events) [95, 96].
The first study to examine renal patients using this tech-
nology was by Braun et al published in 1996 [12]. In reality
this was ahead of its time, and preceded general interest
in this area. By the time of the second publication in 2000
by Goodman et al [13], in a different patient cohort and in
a high-prestige journal, there was a much more receptive
audience. Since then there have been several more full
publications and abstracts [14, 71, 77, 78, 117–121]. These
are summarized in Table 4 (full papers). Even so, to date
there are only data around 500 patients, and only limited
follow up on about 180 of these. In our opinion there is
much more to be understood about what this technology
is able to tell us.
SEVELAMER “TREAT TO GOAL” STUDY
In numerical terms this study, enrolling around 200
subjects, providing a baseline electron beam CT image
in 186, and providing 12 months electron beam CT CAC
and aortic calcification data on (just) 132 subjects is by far
the largest study such involving dialysis patients [14]. The
fact that this was in addition an intervention study, one of
very few in the whole field of electron beam CT (in any
patient grouping), is a cause for celebration for the inves-
tigators, who deserve congratulation for the organization
of this undertaking. The virtual abolition of progression
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Table 3. Possible confounding factors in the interpretation of mainly cross-sectional information about risk factors and vascular calcification
Risk factor Association Confounded by
High plasma phosphate Phenotypic shift of contractile vascular smooth
muscle cells to secretory CVC; mortality data
Is high phosphate a marker of severe bone disease, or
noncompliance with dialysis, drugs, and diet?
High plasma calcium Hypercalcemic episodes leading to direct
precipitation
Hyperparathyroidism, vitamin D; lack of relation
between calcium balance and blood calcium levels
High parathyroid hormone Increases intracellular calcium levels Use of more phosphate binders and vitamin D
Low parathyroid hormone Lack of dynamic bone metabolic activity to
buffer changes in plasma calcium
Previous use of vitamin D and phosphate binders;
parathyroidectomy
Vitamin D therapy Increases plasma calcium and phosphate levels;
calcifies vessel wall tunica media; vitamin D
receptors on vascular smooth muscle cells
(especially with hyperphosphatemia, even if
calcium normal); accelerates atherosclerosis
Hyperparathyroidism
Inflammation/redox stress Reduces levels of alpha-2-Heremann Schmitt
glycoprotein (fetuin) a naturally occurring
inhibitor of calcification; accelerated
atherosclerosis
Vascular disease may be the cause of inflammation
Warfarin Inhibits matrix GLA protein; naturally
occurring inhibitor of calcification
Often used in patients with poor hemodialysis access,
including diabetics, older patients, and women;
sharing risk factors for vascular disease
Dyslipidemia Oxidized low-density lipoprotein causing
endothelial/vascular smooth muscle cell
damage; high-density lipoprotein protective
against calcification
Hyperparathyroidism associated dyslipidemia;
sevelamer reduces low-density lipoprotein
cholesterol and raises high-density lipoprotein
cholesterol
Avoidance of aluminum; high dose
of oral calcium-containing
phosphate binders
Positive calcium balance High plasma phosphate levels; poor compliance with
drugs, dialysis, and diet; alkalosis favors calcification
(calcium carbonate/acetate); sevelamer leads to mild
acidosis; aluminum is a potent inhibitor of
calcification/ossification
CVC is calcifying vascular cells.
of aortic and coronary calcification over 24 months of
follow-up in patients whose plasma phosphate was con-
trolled by sevelamer, in contrast to the progression of vas-
cular calcification seen in matched cohorts given calcium
acetate or carbonate (Fig. 7)—despite the same calcium-
phosphate product—is remarkable, and tells us that rapid
progression of vascular calcification on (hemo)dialysis
can be ameliorated. But crucially, it does not tell us how.
The effects on the CAC score described in the study did
not correlate with any other parameter (in part this may
reflect the complexity of the scoring systems, and the
need for more information about how best to analyze
these rare types of electron beam CT-based progression
studies).
Two recent studies do inform us to some degree about
the significance of electron beam CT-derived CAC scores
in chronic kidney disease patients. Haydar et al [122, 123]
have published two studies, the first of which found a
strong cross-sectional association between CAC and aor-
tic pulse wave velocity (which measure of aortic stiffness
has an impressive association with mortality on dialy-
sis) [122]. In their second report, of even greater interest
was a close association between the degree of coronary
atherosclerosis and the extent of CAC, suggesting that
there may be a similar relationship even in dialysis pa-
tients between extent of CAC and coronary atheroscle-
rosis [123]. If this is confirmed, the implications of high
electron beam CT scores, and the importance of pre-
venting rapid progression of further calcification, are
obvious.
The Treat to Goal Study cannot inform us solely
about the role of oral calcium ingestion in the patho-
genesis of cardiovascular disease. This is because the
comparator drugs (sevelamer hydrochloride and calcium
acetate/carbonate) differed not only in their “calcium
loading/phosphate binding” capacities but also in an ab-
solutely crucial area of relevance, namely, lipid-lowering
capacity, with the sevelamer cohort showing around a
35% reduction in LDL cholesterol values [14]. Seve-
lamer (Renagel) is a hydrogel polymer (poly-allylamine
hydrochloride) which among its properties can boast a
bile-acid sequestrant effect. In a large study sevelamer
reduced LDL cholesterol by 30%, and increased HDL
cholesterol by 18%. Lipid profile changes of a similar
magnitude were seen in the Treat to Goal Study [124].
The importance of this cholesterol modulation effect
cannot be overstated as two recent trials in nonrenal
cohorts have shown that substantial reductions in LDL
cholesterol were associated with reduced progression of
electron beam CT-measured CAC [72, 125]. From the
second of these studies it was shown that in 32 patients
with an LDL cholesterol level <100 mg/dL under treat-
ment, the median relative change in CAC score was 27%
during the untreated versus −3.4% during the treatment
period (P = 0.0001). These data are consistent also with
the small electron beam CT study by Tamashiro et al [71]
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Table 4. Summary of coronary artery calcification (CAC) series (full papers) featuring renal patients
Author, year Number age
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Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; RTx, renal transplantation; DM RD, diabetic renal disease; AWC, aortic wall calcification; AVC,
aortic valve calcification; MVC, mitral valve calcification; HTN, hypertension; BMI, body mass index; SPECT, single photon emission computed tomography; TRIG,
triglycerides.
aThese correlated with CAC but in multiple regression analysis only age was independently associated with CAC.
where more rapid CAC progression in dialysis patients
occurred in those subjects with higher triglyceride, and
lower HDL, levels. Obviously, the role of dyslipidemia in
the etiopathogenesis of atherosclerotic plaques in blood
vessels need not be reprised.
Finally, it must be said that there is in fact only one
other study examining longitudinally the progression of
electron beam CT CAC scores in the same patients. Here
it was shown that the use of calcium channel block-
ers, as opposed to thiazide diuretics, in hypertensive








Week 26 Week 52
Fig. 7. Treatment effects of sevelamer (Renagel) on progression of
coronary calcification in hemodialysis patients (comparator calcium
containing oral phosphate binders) (from [14] with permission of the
authors).
subjects was associated with lesser CAC progression
[126].
We in the renal community, although fortunate indeed
to have a CAC progression study involving an interven-
tion, now urgently need a trial that compares statins,
statins with calcium acetate, and sevelamer to reveal the
relative contribution of lipid-lowering, avoidance of hy-
percalcemia, or other unknown effects. There is increas-
ing evidence of multiple pleiotropic effects of sevelamer
in humans, including alteration of lipid profiles, reduc-
tion in CRP, reduction in uric acid levels, and reduc-
tion in oxidative stress. Any or all of these alternative
mechanisms, with avoidance of hypercalcemia, may be
the explanation for the abolition of progression of vascu-
lar calcification. This is important, as there is no certainty
that other noncalcium containing OPBs will have any of
these additional, and possibly crucial, properties. Thus it
is of great importance that, another nonaluminum, non-
calcium phosphate binder such as ferric chloride, or the
rare earth lanthanum chloride, should be compared to
calcium acetate in the same way. Lanthanum chloride in
vitro has anticalcification/antiatherosclerotic properties
[127]. It would be important to see if these were found
in human studies, despite the minimal absorption of lan-
thanum carbonate as a phosphate binder. Until we have
this additional information either the lipid, or the cal-
cium, explanations (or both) could be valid. Even the
mooted larger long-term survival study in sevelamer vs.
calcium acetate patients will not address this issue ade-
quately, unless it can be controlled for cholesterol values,
as cholesterol-reduction is now known to be associated
with improved survival on dialysis [128].
KEY THINGS WE STILL NEED TO KNOW:
BUILDING THE EVIDENCE CHAIN
In our view the evidence chain we have is incomplete.
Among the things we need to understand better are (1)
the relationship between CAC and aortic calcium scores,
and vessel stiffness; (2) the origin(s) of vascular calcium
(e.g., diet, dialysate, binders, bone) using mass balance
methodology and with detailed analysis of bone turnover;
(3) the importance to any success in impeding vascular
calcification of aggressive lipid-lowering therapy and/or
suppression of vascular inflammation over and above
phosphate-reduction; (4) the complex relationship be-
tween plasma calcium and phosphate levels, vitamin D
dose and levels, and the tendency to ectopic calcifica-
tion; (5) the role of better dialysis strategies (e.g., daily or
long-hours hemodialysis where control of plasma phos-
phate is vastly superior to conventional hemodialysis);
and (6) Whether there is a special “sevelamer”-specific
effect on vascular calcification that is not shared by other
noncalcium-containing OPBs.
The importance of a full and proper understanding
of the very complex inter-relationships between min-
eral metabolism and outcome is beautifully delineated by
Stevens et al [129] in a recent longitudinal study of 515
Canadian dialysis patients. In this report it was shown that
combinations of derangements of calcium, phosphate,
and PTH were much more powerfully predictive than
using individual parameters. Thus, the combinations of
high calcium, phosphate, and high PTH, or low PTH, had
the highest risks for mortality compared to normal cal-
cium, phosphate, and high PTH, which had the lowest
mortality.
When we do fully comprehend the above points, we will
be nearer to understanding how (or even if) we should
employ CT-based techniques to quantify vascular calcifi-
cation extent and progression, or to screen for vascular
disease. Such technologies may however allow for an ac-
curate assessment of incremental calcification with time
on dialysis.
THE NEW (2003) K-DOQI GUIDELINES ON
PHOSPHATE BINDERS IN CHRONIC KIDNEY
DISEASE
In the face of growing concerns about cardiovascu-
lar disease and vascular calcification, a careful process
of evidence review and expert deliberation has resulted
in new guidelines. In general these new recommenda-
tions necessarily come with “opinion” rather than with
“evidence” labels. Very little indeed can be stated with
confidence for predialysis patients, even when to start
phosphate binders, with what binders, to what target
phosphate levels? The following recommendations are
for dialysis patients [130]: (1) initial therapy of raised
phosphate levels [>1.8 mmol/L (5.5 mg/dL)] refractory
to dialysis and diet can be started using either calcium or
nonmetal salt-based phosphate binders; (2) use of a cock-
tail of oral phosphate binders is strongly encouraged, with
a limit of 1.5 g of calcium salts (making a maximum to-
tal of 2 g of elemental calcium per day in conjunction
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with dietary calcium intake); (3) calcium salts should
be avoided in patients with sustained iPTH levels of
<150 pg/mL, or plasma calcium levels of >2.55 mmol/L
(10.2 mg/dL); vitamin D compounds should also be
avoided or ceased with calcium levels of >2.55 mmol/L
(10.2 mg/dL); (4) noncalcium-based binders should be
preferred in patients with severe vascular or soft tissue
calcifications; (5) plasma calcium should be maintained
at the lower end of the normal range [2.1 to 2.35 mmol/L
(8.4 to 9.5 mg/dL)]; and (6) calcium-phosphate product
should be kept <4.4 mmol2/L2 (55 mg2/mL2) by focusing
first on controlling plasma phosphate.
These guidelines suggest a radical shift away from cal-
cium usage. In reality this will mandate the use of a va-
riety of different phosphate binders in many patients if
the central phosphate control targets are to be achieved.
Thus patients on several, or all, of the older phosphate
binders (calcium, magnesium, aluminum) as well as the
new drugs (sevelamer, lanthanum, and iron compounds)
will become much more common. The challenge to con-
trol phosphate (the primary goal) will remain a severe
one. The balance of risk between achieving good phos-
phate control, versus avoiding excess calcium loading,
needs to be determined, given that plasma phosphate
(and emphatically not plasma calcium) has been linked
to mortality on dialysis.
OUR CONCLUSIONS AND
RECOMMENDATIONS
In our view the key issue that should concern us all
is sustained and widespread oversuppression of hyper-
parathyroidism by engendering a net positive calcium
balance for the patient often using both vitamin D and
calcium-containing OPBs. Low-turnover bone states are
the now the norm not only in dialysis patients but also
in predialysis patients as shown by a recent bone-biopsy
study [131]. This tendency is worsened by calibration of
the use of vitamin D by hypercalcemia, rarely by use of
vitamin D levels, and by infrequent plasma iPTH assays
[at best an approximate guide to bone histology—the
conceptual difference is in fact between a random glu-
cose value (iPTH value) and glycated hemoglobin (bone
biopsy)]. iPTH values are at their least clinically pre-
dictive over the range 100–400 pg/mL (which is where
we try to engineer the majority of patients). Intact os-
teocalcin and bone-specific alkaline phosphatase may be
more useful tools which should be tested prospectively
in clinical trials [132, 133]. A whole paradigm shift in the
treatment of hyperparathyroidism and ectopic calcifica-
tion may well be close at hand, with the imminent clinical
emergence of the calcimimetic compounds [134, 135].
Many further studies are urgently needed to compre-
hend the fascinating and highly complex biology of dis-
ordered vascular calcification in the setting of chronic
renal failure. Vascular calcification in renal patients, like
the presence of cardiac valvular calcification in dialysis
patients [136], may be a marker of increased cardiovas-
cular risk, well before the actual presence of the calcium
has caused a major functional perturbation, perhaps the
dialysis patients’ equivalent of microalbuminuria in di-
abetes or hypertension [137]? With our present level of
knowledge, which is heavily skewed by a single interven-
tional study, it is premature in our opinion to do more
than to pay much greater attention to successful manipu-
lation of plasma phosphate levels by better dialysis tech-
niques, better patient education about diet and phosphate
binders, avoidance of marked or prolonged positive cal-
cium balance, calibrating the use of vitamin D more suc-
cessfully. Further research on the mechanism of action
of sevelamer on vascular calcification is urgently needed.
Also, in the light of numerous clinical and experimental
studies in renal and nonrenal subjects establishing a link
between dyslipidemia and propensity to vascular calcifi-
cation, having a low threshold for the use of statin-based
lipid-lowering therapy in a group of patients with the du-
bious distinction of having the greatest measured major
adverse cardiovascular event rates of any reported pa-
tient cohorts is, in our opinion, mandatory, unless a large-
scale randomized controlled trial shows no benefit.
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